• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

晚期上皮性卵巢癌的新辅助化疗：一项生存研究。

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study.

作者信息

Baruah Upasana, Barmon Debabrata, Kataki Amal Chandra, Deka Pankaj, Hazarika Munlima, Saikia Bhargab J

机构信息

Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute (RCC), Guwahati, Assam, India.

Department of Medical Oncology, Dr. B. Borooah Cancer Institute (RCC), Guwahati, Assam, India.

出版信息

Indian J Med Paediatr Oncol. 2015 Jan-Mar;36(1):38-42. doi: 10.4103/0971-5851.151781.

DOI:10.4103/0971-5851.151781
PMID:25810573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4363849/
Abstract

CONTEXT

Patients with advanced ovarian cancer have a poor prognosis in spite of the best possible care. Primary debulking surgery has been the standard of care in advanced ovarian cancer; however, it is associated with high mortality and morbidity rates as shown in various studies. Several studies have discussed the benefit of neoadjuvant chemotherapy in patients with advanced ovarian cancer.

AIMS

This study aims to evaluate the survival statistics of the patients who have been managed with interval debulking surgery (IDS) from January 2007 to December 2009.

MATERIALS AND METHODS

During the period from January 2007 to December 2009, a retrospective analysis of 104 patients who underwent IDS for stage IIIC or IV advanced epithelial ovarian cancer at our institute were selected for the study. IDS was attempted after three to five courses of chemotherapy with paclitaxal (175 mg/m(2) ) and carboplatin (5-6 of area under curve). Overall survival (OS) and progression free survival (PFS) were compared with results of primary debulking study from existing literature. OS and PFS rates were estimated by means of the Kaplan-Meier method. Results were statistically analyzed by IBM SPSS Statistics 19.

RESULTS

The median OS was 26 months and the median PFS was 18 months. In multivariate analysis it was found that both OS and PFS was affected by the stage, and extent of debulking.

CONCLUSIONS

Neoadjuvant chemotherapy, followed by surgical cytoreduction is a promising treatment strategy for the management of advanced epithelial ovarian cancers.

摘要

背景

尽管接受了最佳治疗，晚期卵巢癌患者的预后仍然很差。初次肿瘤细胞减灭术一直是晚期卵巢癌的标准治疗方法；然而，如各项研究所显示，它与高死亡率和发病率相关。多项研究讨论了新辅助化疗对晚期卵巢癌患者的益处。

目的

本研究旨在评估2007年1月至2009年12月期间接受间歇性肿瘤细胞减灭术（IDS）治疗的患者的生存统计数据。

材料与方法

在2007年1月至2009年12月期间，对我院104例接受IDS治疗IIIC期或IV期晚期上皮性卵巢癌的患者进行回顾性分析，以纳入本研究。在使用紫杉醇（175mg/m²）和卡铂（曲线下面积5-6）进行三至五个疗程的化疗后尝试进行IDS。将总生存期（OS）和无进展生存期（PFS）与现有文献中初次肿瘤细胞减灭术研究的结果进行比较。通过Kaplan-Meier法估计OS和PFS率。结果采用IBM SPSS Statistics 19进行统计学分析。

结果

中位OS为26个月，中位PFS为18个月。多因素分析发现，OS和PFS均受分期和减瘤范围的影响。

结论

新辅助化疗后进行手术细胞减灭术是治疗晚期上皮性卵巢癌的一种有前景的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad46/4363849/976e05dcb6ae/IJMPO-36-38-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad46/4363849/fab529d30c7d/IJMPO-36-38-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad46/4363849/9271e82e5397/IJMPO-36-38-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad46/4363849/1de47b997b9a/IJMPO-36-38-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad46/4363849/976e05dcb6ae/IJMPO-36-38-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad46/4363849/fab529d30c7d/IJMPO-36-38-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad46/4363849/9271e82e5397/IJMPO-36-38-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad46/4363849/1de47b997b9a/IJMPO-36-38-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad46/4363849/976e05dcb6ae/IJMPO-36-38-g006.jpg

相似文献

1
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study.晚期上皮性卵巢癌的新辅助化疗：一项生存研究。
Indian J Med Paediatr Oncol. 2015 Jan-Mar;36(1):38-42. doi: 10.4103/0971-5851.151781.
2
Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.初次肿瘤细胞减灭术与新辅助化疗后间隔肿瘤细胞减灭术治疗晚期卵巢癌的疗效比较。
Arch Gynecol Obstet. 2016 Jan;293(1):163-168. doi: 10.1007/s00404-015-3813-z. Epub 2015 Jul 22.
3
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.高级别晚期卵巢癌的初次肿瘤细胞减灭术与初次新辅助化疗：生存比较。
Radiol Oncol. 2018 Sep 11;52(3):307-319. doi: 10.2478/raon-2018-0030.
4
Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.Ⅲc-IV期高级别浆液性卵巢癌患者新辅助化疗后行间隔减瘤手术预后的潜在风险因素
J Obstet Gynaecol Res. 2018 Sep;44(9):1808-1816. doi: 10.1111/jog.13710. Epub 2018 Jul 18.
5
[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].[晚期上皮性卵巢癌中间减瘤手术的再评估]
Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60.
6
Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.优化卵巢癌治疗：新辅助化疗和间隔肿瘤缩小术与初始肿瘤细胞减灭术治疗可能无法实现理想切除的上皮性卵巢癌。
Gynecol Oncol. 2017 Feb;144(2):266-273. doi: 10.1016/j.ygyno.2016.11.021. Epub 2016 Dec 1.
7
The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.新辅助化疗的周期数与IIIC-IV期高级别浆液性卵巢癌的预后相关。
Arch Gynecol Obstet. 2017 Feb;295(2):451-458. doi: 10.1007/s00404-016-4256-x. Epub 2016 Dec 3.
8
Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.威尔士西南部晚期卵巢癌的管理——在一个未经选择的连续患者队列中，对初次肿瘤细胞减灭术和初始化疗治疗策略的比较
Cancer Epidemiol. 2017 Aug;49:85-91. doi: 10.1016/j.canep.2017.05.014. Epub 2017 Jun 7.
9
Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.时机至关重要：晚期卵巢癌初次或间隔减瘤手术后的腹腔内化疗。
Cancer Chemother Pharmacol. 2018 Jul;82(1):55-63. doi: 10.1007/s00280-018-3591-y. Epub 2018 Apr 27.
10
Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.晚期卵巢癌行初次肿瘤细胞减灭术或新辅助化疗后间隔减瘤术。
Eur J Cancer. 2011 Sep;47 Suppl 3:S88-92. doi: 10.1016/S0959-8049(11)70152-6.

引用本文的文献

1
Critical Analysis of Advanced High-Grade Serous Epithelial Ovarian Cancer in Women: An Experience of 100 Cases from a Regional Cancer Center in Northeast India.印度东北部某地区癌症中心100例女性晚期高级别浆液性上皮性卵巢癌的批判性分析。
South Asian J Cancer. 2023 Aug 7;12(4):334-340. doi: 10.1055/s-0043-1771444. eCollection 2023 Oct.
2
Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?新辅助化疗后最佳细胞减灭术是晚期卵巢癌唯一的预后因素吗？
South Asian J Cancer. 2022 Dec 30;11(3):207-212. doi: 10.1055/s-0042-1755291. eCollection 2022 Jul.
3
Vitamin D and DDX4 regulate the proliferation and invasion of ovarian cancer cells.

本文引用的文献

1
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.新辅助化疗与初始肿瘤细胞减灭术用于 IIIC 或 IV 期卵巢癌。
N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.
2
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.广泛上腹部手术在原发性卵巢癌、输卵管癌和腹膜癌肿瘤细胞减灭术中的主要并发症发生率。
Gynecol Oncol. 2010 Oct;119(1):38-42. doi: 10.1016/j.ygyno.2010.05.031. Epub 2010 Jul 6.
3
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).
维生素D和DDX4调节卵巢癌细胞的增殖和侵袭。
Oncol Lett. 2018 Jul;16(1):905-909. doi: 10.3892/ol.2018.8718. Epub 2018 May 16.
4
Surgical treatment pattern and outcomes in epithelial ovarian cancer patients from a cancer institute in Kerala, India.印度喀拉拉邦一家癌症研究所上皮性卵巢癌患者的手术治疗模式及结果
Ecancermedicalscience. 2016 Feb 4;10:619. doi: 10.3332/ecancer.2016.619. eCollection 2016.
5
Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.中心体蛋白55的上调与上皮性卵巢癌的不良预后和肿瘤侵袭相关。
Tumour Biol. 2016 May;37(5):6239-54. doi: 10.1007/s13277-015-4419-6. Epub 2015 Nov 28.
手术结果作为晚期上皮性卵巢癌预后因素的作用：三项前瞻性随机3期多中心试验的联合探索性分析：由妇科肿瘤学 Arbeitsgemeinschaft 卵巢癌研究小组（AGO-OVAR）和国家卵巢癌研究调查小组（GINECO）开展
Cancer. 2009 Mar 15;115(6):1234-44. doi: 10.1002/cncr.24149.
4
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.卵巢癌。《国际妇产科联盟（FIGO）第26届妇科癌症治疗结果年度报告》
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92. doi: 10.1016/S0020-7292(06)60033-7.
5
Malnutrition among gynaecological cancer patients.妇科癌症患者中的营养不良问题。
Eur J Clin Nutr. 2007 May;61(5):642-6. doi: 10.1038/sj.ejcn.1602540. Epub 2006 Oct 4.
6
The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer.化疗前血红蛋白水平在卵巢癌患者中的预后作用。
Front Biosci. 2006 May 1;11:1585-90. doi: 10.2741/1906.
7
Morbidity of cytoreductive surgery in the elderly.
Am J Obstet Gynecol. 2004 May;190(5):1398-400. doi: 10.1016/j.ajog.2004.01.078.
8
Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study.晚期卵巢癌间歇性肿瘤细胞减灭术的结果：一项暴露-非暴露研究
Ann Oncol. 2003 Jan;14(1):74-7. doi: 10.1093/annonc/mdg003.
9
Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma.
Int J Gynecol Cancer. 2001 Nov-Dec;11(6):466-70. doi: 10.1046/j.1525-1438.2001.01064.x.
10
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.铂类时代最大程度肿瘤细胞减灭术对晚期卵巢癌的生存影响：一项荟萃分析。
J Clin Oncol. 2002 Mar 1;20(5):1248-59. doi: 10.1200/JCO.2002.20.5.1248.